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INTRODUCTION
Neurofibromatosis type 1 (NF1), previously
termed as von Recklinghausen’s disease, is a com-
mon neurocutaneous condition with an autosomal
dominant pattern of inheritance. Its birth incidence
is approximately of one in 2500 and the minimum
prevalence one in 4000-5000 (1). The disease has
variable clinical expression and severity. Diverse as-
sociated complications have been described, involv-
ing any organ system and ranging from body and
facial disfigurement, scoliosis and distinctive bony
dysplasias with or without pseudoarthrosis and
vasculopathies (cardiovascular and cerebrovascular
diseases) to cognitive function impairment and ma-
lignant conditions (peripheral nerve sheath tumors,
central nervous system gliomas, leukaemia, rhab-
domyosarcoma and pheochromocytoma) (2).
In particular, NF1 affects the respiratory system
in various ways : chest wall abnormalities (cutane-
ous and subcutaneous neurofibromas, kyphoscolio-
sis, rib notching from intercostal neurofibroma) ;
primary thoracic or metastatic neural tumors ; in-
terstitial fibrosis with bibasilar predominance with
or without asymmetric upper lobe cystic and bullous
disease ; pulmonary arterial hypertension, spontane-
ous massive haemothorax ; central alveolar hypov-
entilation ; bilateral diaphragmatic paralysis ; medi-
astinal involvement (lateral meningocele) (3 -9).
Eosinophilic lung diseases have not so far been
reported as associated complications of NF1. A case
of chronic eosinophilic pneumonia in a patient with
CASE REPORT
Chronic eosinophilic pneumonia associated with neurofi-
bromatosis type 1 : an unusual complication
Stamatis Katsenos1,3, Melita Nikolopoulou1, Efstathios Rallis2, and
Stavros H Constantopoulos3
1Department of Pneumonology, and 2Department of Dermatology, Army General Hospital of Athens,
Athens, Greece ; and 3Department of Pneumonology, University Hospital of Ioannina, Ioannina,
Greece
Abstract : Neurofibromatosis type 1 (formerly known as von Recklinghausen’s disease) is
an autosomal dominant disorder, which results from the proliferation of the neural crest
cells, thus affecting any organ system. Several pulmonary manifestations have hitherto
been reported, including chest wall deformities, diffuse lung disease, thoracic neoplasms,
pulmonary arterial hypertension, central hypoventilation, diaphragmatic paralysis and
meningocele. However, eosinophilic lung disorders have not been described. An unusual
case of chronic eosinophilic pneumonia in a patient with neurofibromatosis type 1, is
reported herein. He had a propitious outcome, following corticosteroid treatment. This
is the first well-documented case of chronic eosinophilic pneumonia and neurofibroma-
tosis type 1 in the same patient. These clinical entities might share common pathogenic
mechanisms, as suggested by the present study, that could explain their co-existence.
J. Med. Invest. 56 : 64-69, February, 2009
Keywords : bronchoalveolar lavage, chronic eosinophilic pneumonia, neurofibromatosis-1, peripheral eosinophilia
Received for publication August 1, 2008 ; accepted October 7,
2008.
Address correspondence and reprint requests to Stamatis
Katsenos, MD, 3, Ierarhou Panaretou St, 45445, Ioannina, Greece
and Fax : +302651029432.
The Journal of Medical Investigation Vol. 56 2009
64
NF1 is described herein ; the patient recuperated
with appropriate corticosteroid treatment.
CASE REPORT
A 25-year-old male non-smoker was referred to
us because of dry cough and exertional breathless-
ness. The onset of symptoms dates from the previ-
ous four weeks with gradual worsening. His past
medical history was unremarkable.
On physical examination, multiple café-au-lait
macules (6), oval with fairly smooth margins meas-
uring 1.5 cm or greater in diameter, were distrib-
uted over the trunk and extremities (Figure 1).
Freckles were also seen in both the axillary regions.
On palpation, several firm subcutaneous papules
scattered on the trunk were identified (Figure 1). A
painful subcutaneous nodule on the right thigh was
also detected. Chest auscultation showed sparse in-
spiratory squeaks throughout the upper and middle
lung fields. The remainder of the clinical examina-
tion was unremarkable.
Basic laboratory tests were normal except for pe-
ripheral blood eosinophilia (2910 cells/μl), slightly
increased erythrocyte sedimentation rate (25 mm/
h), elevated serum C-reactive protein (9 mg/dl) and
eosinophilic cationic protein (ECP) levels (196 μg/
l). Arterial blood gases while breathing room air
showed mild hypoxemia (PaO2 : 70 mmHg, PaCO2 :
34 mmHg, pH : 7.44 and bicarbonate 24.5 mmol/l).
Further investigations, which included antinuclear
antibodies, C- and P-antineutrophilic cytoplasmatic
antibodies, immunoglobulin levels, IgE antibody for
specific allergens and serum complement analysis
were unremarkable.
Skin tests for both M. tuberculosis and atypical
mycobacteria were negative. Repetitive serologic
tests and stool examination had no effect on the de-
tection of parasites ova. Pulmonary function tests in
conjunction with pulmonary diffusing capacity (sin-
gle breath CO test) were within normal limits.
Chest X-ray revealed peripheral opacities in the
left upper lung field, which represented alveolar con-
solidation (Figure 2). A high resolution chest com-
puted tomography (HRCT) disclosed bilateral air
space consolidations located in the periphery of the
upper lobes as well as ground-glass opacities in the
lingula (Figure 3a, b). A second chest X-ray, three
days later demonstrated a nodular infiltrate in the
right lower lung field with attenuation of left upper
lung field opacities ; findings compatible with a mi-
gratory-like pattern.
The patient underwent fiberoptic bronchoscopy
which showed only slight mucosal redness in the
whole tracheobronchial tree. Bronchoalveolar lavage
(BAL) was performed from the left upper lobe and
lingula. BALF differential cell counts revealed 48%
eosinophils, 32% alveolar macrophages, 16% lympho-
cytes and 3.8% neutrophils. All the microbiology
Figure 1. Café-au- lait spot and subcutaneous papules dis-
persed over the trunk.
Figure 2. Chest radiograph showing peripheral alveolar opaci-
ties in the left upper lobe.
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studies of BAL samples provided no evidence for
bacterial, fungal or viral infection. Cytologic exami-
nation was also negative.
Bone marrow aspiration and biopsy were normal.
Slit lamp examination revealed reddish brown spots
within the lower pole of the irises, compatible with
Lisch nodules (Figure 4). Excisional biopsy of the
subcutaneous nodule on the right thigh was typical
of neurofibroma. Additional work-up, including com-
puted tomography of the abdomen, magnetic reso-
nance imaging of the brain, long bones plain radio-
graphs, as well as Doppler echocardiography dis-
closed no abnormalities.
The diagnosis of chronic eosinophilic pneumonia
and NF1 was eventually established. The patient was
started on prednisone 40 mg/day with rapid im-
provement of his clinical picture and chest imaging
features normalization within two weeks. The initial
prednisone dose was effectively tapered down over
a period of several months, with a schedule of the
steroid therapy completion in a year.
DISCUSSION
We report a case of a patient with known neurofi-
bromatosis type 1 (NF1), who presented with chronic
eosinophilic pneumonia, suggesting that NF1 may
promote the development of chronic eosinophilic
pneumonia.
NF1 is a comparatively common autosomal domi-
nant neurocutaneous syndrome with a prevalence
rate of about 1 per 4000-5000 (1). There is no fam-
ily history of this disorder in approximately half of
the patients, suggesting that spontaneous muta-
tions are tangible. The gene liable for the NF1,
called NF1 gene, has been identified on chromo-
some 17q11.2. Its protein product, neurofibromin, is
a negative regulator of cell proliferation and differ-
entiation, functioning as a tumor suppressor (10).
Although recent developments in molecular genetic
testing confirm the diagnosis of NF1 in over 95% of
patients, its diagnosis is still based mostly on pub-
lished clinical criteria (11), (Table 1). In the present
case, four major criteria were considered sufficient
to support the diagnosis of NF1.
Chronic eosinophilic pneumonia is a distinct dis-
ease of unknown aetiology often accompanied by
allergic diatheses, mainly asthma, which can ante-
date the condition by many years or can develop
Figure 3a. High resolution chest computed tomography
(HRCT) illustrating bilateral air space consolidations located in
the periphery of the upper lobes.
Figure 3b. HRCT depicts ground-glass opacities in the lingual.
Figure 4. Lisch nodules.
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concurrently (12). Although firm diagnostic criteria
are not available, the diagnosis can be derived from
the combination of : (i) non-specific pulmonary
symptoms (usually over two weeks duration), (ii)
pulmonary opacities that are in most cases bilateral,
peripheral and migratory, (iii) pronounced blood
and/or alveolar eosinophilia (blood eosinophilic
count1000/mm3, bronchoalveolar lavage eosino-
philis40%) and (iv) absence of any known cause
of pulmonary eosinophilia (13). The hallmark of
chronic eosinophilic pneumonia is a rapid and re-
markable resolution of clinical, radiological and bio-
logical features with oral corticosteroids. In our pa-
tient this resolution occurred in two weeks.
Neurofibromatosis type 1 is an extremely variable
condition in terms of its features occurrence and
severity. Some afflicted patients have mild manifes-
tations, whereas others experience more severe
complications reducing life expectancy (1, 2). Mild
cases may be missed, since affected individuals sel-
dom seek medical attention. The present case was
revealed by a compulsory physical examination as
part of health evaluation for military service. The
presenting respiratory symptoms, just before join-
ing the army, forced our patient to ask further medi-
cal assistance, thus leading to the definite diagnosis.
A multitude of phenotypic features has been de-
scribed in NF1, as virtually any organ can be af-
fected by this neurocutaneous disorder. Especially,
NF1 has a variety of manifestations in the thorax
and lungs, as mentioned previously (3 - 9). Never-
theless, pulmonary eosinophilic disorders have not
been reported to date in association with NF1.
Search of the literature revealed only a report of
NF1 complicated by acute lymphoblastic leukaemia
(ALL) and hypereosinophilia (14).
The authors postulate that the occurrence of
chronic eosinophilic pneumonia may be facilitated
by neurofibromatosis type 1. It is firmly thought that
nerve growth factor (NGF) plays a pivotal role in
this relationship. Compelling circumstantial evidence
suggests that NGF is involved in the pathogenesis
of neurofibromatosis and its neurological compli-
cations (mainly neural tumors) (15 -17). Indeed,
high NGF plasma levels were detected in patients
with NF1 (18).
However, several lines of evidence have also im-
plicated NGF in the pathophysiology of various al-
lergic diseases (19). Strictly speaking, NGF has
been shown to interact with non-neuronal cells in-
volved in innate and adaptive immune systems, such
as lymphocytes, mast cells, macrophages, basophils
and eosinophils themselves. Therefore, it intervenes
in allergy-related immune cell functional activities,
such as mast-cell degranulation, Th2 cytokine syn-
thesis and release, antibody production from B cells
and eosinophil survival (20).
Mast cells and eosinophils, the major key effector
cells in allergic inflammation, are a source of NGF
and influenced by it in their differentiation, survival
and activation (21, 22). This mast cell-eosinophil
cross-talk, through NGF and other specific pre-
formed mediators, can perpetuate and even inten-
sify allergic inflammatory process with possible de-
velopment of tissue damage.
The magnitude of NGF involvement in the inflam-
matory stages of allergy has not only been shown
in animal models or in vitro studies, but also in pa-
tients with allergic diseases and especially bronchial
asthma, the best studied eosinophilic lung disorder.
The expression of NGF is highly up-regulated and
significantly correlated with the increased airways
mast cells in asthmatic patients (23). Furthermore,
enhanced NGF plasma and BAL levels are strongly
correlated with atopy markers, disease severity and
the development of bronchial hyperresponsiveness,
suggesting that NGF mediates activation of bron-
chial eosinophils and substantially regulates eosino-
philic inflammation in asthma (24). Similar immuno-
pathogenic mechanisms have been observed in
chronic eosinophilic pneumonia, lacking however
any evidence on NGF involvement (12).
Recent studies in mice models demonstrate that
Nf1 deficiency results in increased numbers of im-
mature and mature T cell subsets, as well as mast
cells ; the latter ones might contribute to neurofibro-
mas development through the release of several cy-
tokines (10, 25). Antigenic stimulation may elicit T-
lymphocytes and mast cells activation, which may
be primed by Nf1 gene mutations. As mentioned
earlier, these cells are a source of NGF, which in
Table 1. Diagnostic criteria for neurofibromatosis type 1 (NF1)
(adapted from ref.11)
Six or more café-au- lait spots0.5 cm in prepubertal children
and1.5 cm in postpubertal individuals
Axillary or inguinal freckling
Two or more cutaneous neurofibromas
One plexiform neurofibroma
Two or more iris Lisch nodules
An optic glioma
A characteristic bony lesion (pseudarthrosis, hypoplasia of
sphenoid wing, severe kyphoscoliosis)
First degree relative with NF1
In order to make the diagnosis, at least two major criteria are
required.
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turn is the major key mediator that might orches-
trate the eosinophilic airway inflammation, thus lead-
ing to the occurrence of chronic eosinophilic pneu-
monia (26). This immunological response could also
be subserved by genetic factors that are hinted by
a history of asthma and atopy in patient’s brother.
Based on the aforementioned data concerning the
role of NGF in NF1 and allergic inflammatory dis-
eases, we measured NGF levels in the patient’s se-
rum and BAL using a highly sensitive NGF-spe-
cific two-site enzyme- linked immunosorbent assay
(ELISA) -kit (Promega, Madison, WI, USA). Both
NGF plasma and BAL levels were significantly in-
creased (157 pg/ml and 235 pg/ml respectively with
normal levels 3.81.7 pg/ml and 53.920.2 pg/
ml). This may demonstrate a possible association
among NF1, NGF and chronic eosinophilic pneumo-
nia.
In conclusion, these observations suggest that
chronic eosinophilic pneumonia could be included
among potential pulmonary manifestations of NF1.
Although a causal association between NF1 and
chronic eosinophilic pneumonia cannot be explicitly
ascertained from this descriptive study, we suggest
that priming of specific immune cells by NF1 may
generate chronic eosinophilic pneumonia, supported
by further triggering factors (e.g. drugs, environ-
mental exposure, bacterial and viral infections).
These remarks may prompt studies on NGF involve-
ment in chronic eosinophilic pneumonia.
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